XML 55 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 9 Months Ended
Sep. 30, 2014
Segment Reporting [Abstract]  
Operating Segment And Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and net loss before taxes. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
We have two complementary reportable operating segments, Laboratory Services and Genetic Assays and Platforms.
 
Segment information for the three months ended September 30, 2014 and 2013 was as follows: 
 
Dollars in Thousands
 
Three Months Ended September 30, 2014
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
4,063

 
$
2,309

 
$
6,372

Gross Profit
1,781

 
434

 
2,215

Net (Loss) Income before Taxes
(3,305
)
 
3,199

 
(106
)
Income Tax Expense (Benefit)
41

 
(67
)
 
(26
)
Net (Loss) Income
$
(3,346
)
 
$
3,266

 
$
(80
)
Depreciation/Amortization
$
544

 
$
45

 
$
589

Interest Expense, net
$
92

 
$
70

 
$
162

 
 
 
 
 
 
 
September 30, 2014
Total Assets
$
23,998

 
$
6,850

 
$
30,848


 
 
 
 
 
 
 
Dollars in Thousands
 
Three Months Ended September 30, 2013
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
4,112

 
$
2,534

 
$
6,646

Gross Profit
1,776

 
674

 
2,450

Net Loss before Taxes
(4,375
)
 
(1,185
)
 
(5,560
)
Income Tax Expense (Benefit)
—

 
(8
)
 
(8
)
Net Loss
$
(4,375
)
 
$
(1,177
)
 
$
(5,552
)
Depreciation/Amortization
$
606

 
$
65

 
$
671

Interest Expense, net
$
96

 
$
59

 
$
155

 
 
 
 
 
 
 
September 30, 2013
Total Assets
$
23,648

 
$
9,532

 
$
33,180


Segment information for the nine months ended September 30, 2014 and 2013 was as follows:

 
Dollars in Thousands
 
Nine Months Ended September 30, 2014
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
11,594

 
$
7,793

 
$
19,387

Gross Profit
4,903

 
2,199

 
7,102

Net (Loss) Income before Taxes
(9,565
)
 
1,887

 
(7,678
)
Income Tax Expense (Benefit)
590

 
(119
)
 
471

Net (Loss) Income
$
(10,155
)
 
$
2,006

 
$
(8,149
)
Depreciation/Amortization
$
1,422

 
$
148

 
$
1,570

Interest Expense, net
$
282

 
$
208

 
$
490

 
 
 
 
 
 

 
Dollars in Thousands
 
Nine Months Ended September 30, 2013
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
12,551

 
$
8,775

 
$
21,326

Gross Profit
5,822

 
2,856

 
8,678

Net Loss before Taxes
(9,641
)
 
(2,312
)
 
(11,953
)
Income Tax Expense
—

 
52

 
52

Net Loss
$
(9,641
)
 
$
(2,364
)
 
$
(12,005
)
Depreciation/Amortization
$
1,815

 
$
287

 
$
2,102

Interest Expense, net
$
314

 
$
145

 
$
459

 
 
 
 
 
 



Net sales for the three and nine months ended September 30, 2014 and 2013 by country were as follows:
 
 
Dollars in Thousands
 
Dollars in Thousands
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2014
 
2013
 
2014
 
2013
United States
$
5,102

 
$
5,095

 
$
14,735

 
$
16,241

Italy
301

 
398

 
1,023

 
1,225

All Other Countries
969

 
1,153

 
3,629

 
3,860

Total
$
6,372

 
$
6,646

 
$
19,387

 
$
21,326


Other than the countries specifically identified above, no country individually accounted for more than 5% of total net sales.

Approximately 99% of our long-lived assets are located within the United States.